Clinical Trial Update: A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating sacituzumab govitecan at an alternative dose and schedule in advanced triple-negative breast cancer is recruiting, sponsor…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Sacituzumab Govitecan (Trodelvy) (sacituzumab govitecan)

Snippet

Sponsor: Gilead Sciences | Conditions: Triple Negative Breast Cancer | Phase 1, Phase 2 | Status: RECRUITING